Researchers devise transport capsule containing E. coli to help fight pneumococcal diseases -
Most people recoil at the idea of ingesting E. coli . But if headlines bacteria could be used to fight against the disease?
Researchers are experimenting with harmless strains of E. coli - yes, the majority of E. coli are safe and important for healthy human digestion - work for reach this goal. Specifically, they have developed a E. coli based transport capsule designed to help new generation vaccines are more effective and more efficient than current vaccines.
The research, described in (link to insert study) of the study published today (1 July) in the journal science advances , highlights the success of the capsule the fight against pneumococcal disease, an infection that can cause pneumonia, septicemia, ear infections and meningitis.
"It is somewhat ironic given you here about E. coli , but there are many strains of bacteria, most of which are quite normal in the body that have great potential in the fight against the disease, "said Blaine A. Pfeifer, PhD, associate professor of chemistry and bioengineering at the University of Buffalo School of engineering and Applied Sciences.
Pfeifer is the lead co-leader of the study author and his former student Charles H. Jones, Ph.D., who directs the marketing efforts of the biotech CEO and founder of Buffalo, New York-based startup Abcombi . Biosciences
the core of the capsule is harmless E. coli Around the bacteria, the researchers wrapped a synthetic polymer. - called poly (amino ester beta) - as a fence chain link. the positive charged polymer associated with the cell wall of bacteria responsible negatively, creating a sort of hybrid capsule.
To test the capsule, the researchers then inserted a vaccine based on proteins, was also marketed by Abcombi, designed to fight against pneumococcal disease. The results, when tested in mice, were impressive
The hybrid design of the capsule provided :.
- Both passive and active targeting of specific immune cells called antigen presenting cells that trigger an immune response.
- Natural and multicomponent adjuvant properties that enhance the body's immune response.
- dual intracellular delivery mechanisms to direct a particular immune response.
- Simultaneous production and delivery of components (antigens) needed for a vaccine.
- high vaccine protection capabilities against pneumococcal disease.
It is also relatively inexpensive to create and flexible in terms of use. For example, the capsule may be used as a delivery device of therapies that target cancer, infectious diseases of viral origin and based on other diseases.
EmoticonEmoticon